Desang diabetes magazine diabetes news



In an online article published in January

2016 by Stacy Lawrence, it was reported

that, 'the U.S. National Institutes of Health

(NIH) is financing what's expected to be

the largest long-term clinical study for

an artificial pancreas (AP) to regulate the

blood sugar levels in Type 1 diabetics

to the tune of $12.7 million. This is the

biggest chunk it's yet doled out as part

of a program the agency started in 2014

to promote testing of artificial pancreas

systems and which has already backed

at least three other research efforts.

The latest funding is going to TypeZero

Technologies, which licensed the artificial

pancreas prototype currently being

called 'inControl AP' from the University

of Virginia in 2013 and has since been

testing and developing applications for it.

A 240-patient, nine-site U.S. and

European six-month trial is slated to start

early this year and lead into a second trial

in a subset of 180-patients that will be

followed for an additional six months to

further test the algorithm used. The first

trial will compare the artificial pancreas

to a control of a standard insulin pump

to comparatively assess how well bloodsugar levels are

controlled and whether

the risk of hypoglycemia was reduced.

Type Zero's health app




A non-invasive and side effect free

neuro-stimulating device that has been

transforming the lives of diabetes sufferers

across Europe by reducing the pain of

peripheral nerve pain is now available in

the UK.

Using the Aptiva system, FREMS

(frequency rhythmic electrical modulation

system) is a series of two-phase,

asymmetrically balanced electric pulses,

delivered via dedicated transcutaneous

disposable electrodes placed along the

pathway of the nerve involved in the


The recommended course of

treatment is for three periods of ten

35-minute sessions over a 2-3 week

period, with a three-month break between

each ten-session period. Aptiva is already

in use at Diabetes and Neurological clinics

in Italy, the Netherlands, Belgium and


Up to 50% of people with diabetes

in the UK will suffer from some degree

of Diabetic Peripheral Neuropathy (DPN)

with symptoms ranging from mild tingling

and aching to chronic severe pain. As

well as pain, DPN is the primary cause

of diabetic foot ulcerations, which in turn

are the major cause of lower limb diabetic


Bharat Vadukul, Business Director of

BHR Pharmaceuticals Ltd, the company

behind the UK launch of Aptiva, says,

'We are delighted to be bringing Aptiva

to the UK. As the research shows, the

device can provide a helpful addition to

the treatment already available for pain

management of DPN, with no significant

side effects.'

The FreeStyle Libre system has been

approved in the UK for use by children

and young people with diabetes aged 4 to

17 years. The FreeStyle Libre system

is designed to give parents peace of mind

because it automatically captures the

glucose readings through day and night.

With Libre sensors, it's possible to monitor

a child's glucose level without routinely

pricking their fingers, especially when

they are sleeping. With use, the FreeStyle

Libre system can provide a deeper

understanding of glucose patterns.



  1. Desang Diabetes Magazine
  2. Accu-Chek Mobile blood glucose system
  3. Desang diabetes magazine diabetes information
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes magazine diabetes news
  7. Desang diabetes magazine diabetes news
  8. Desang diabetes magazine diabetes diet
  9. Page 0009
  10. Desang diabetes magazine diabetes diet
  11. hypo awareness programme
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Ascensia Contour Diabetes blood test meters
  18. Making Carbs Count
  19. Making Carbs Count
  20. Making Carbs Count
  21. Accu-Chek Insight insulin pump
  22. Desang diabetes kitbags

Related Issues